OSI present data on dual 5-HT1A agonist/Monoamine reuptake inhibitor « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

OSI present data on dual 5-HT1A agonist/Monoamine reuptake inhibitor

Posted on June 10, 2008 by crimsoncanary

OSI have presented preclinical data on its dual 5-HT1A agonist/Monoamine reuptake inhibitor PSN602 which is under development for the treatment of obesity. It was found to cause equivalent weight loss in rats to Sibutramine

Filed under: gpcr | Tagged: 5-HT1A, 5HT1A, agonist, OSI, Preclinical

« OSI present data on its GPR119 agonist for Type 2 diabetes NeurogesX publish Phase III data on NGX-4010 in HIV neuropathy »

Leave a Reply